BioSpace News Archive

The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose

Alcohol Awareness Month Reminds Parents to Prepare Kids for Prom, Graduation Parties

New Kaiser Permanente research also shows decreased overdose risk for patients who discontinued long-term opioid therapy [19-April-2019] DENVER , April 19, 2019 /PRNewswire/ -- Patients prescribed opioid pain medications whose doses varied over time were 3 times more likely to experience an overdose than patients prescribed stable opioid doses, according to an obser

Writing in the April issue of The American Journal of Managed Care® (AJMC®), researchers examining diabetes care in Minnesota clinics found that publicly reporting care measures did not result in health systems improving their lower-performing clinics enough to compete with higher-performing competitors

BioEnterprise is pleased to announce the winners of the Third Annual Medical Capital Innovation Competition (MCIC), awarded yesterday at the Global Center for Health Innovation.

Eight patients who took the popular HIV/AIDS drug Truvada and similar tenofovir-based drugs have sued Gilead Sciences, Inc., claiming the giant pharmaceutical company deliberately withheld a much safer version of these drugs from the market for more than a decade in a patent-timing scheme to maximize profits.

Young Living Essential Oils, the world leader in essential oils, announced the promotion of Sarah Bjorgaard as General Manager, U.S. Market

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has approved a one-for-twenty reverse stock split of its issued and outstanding shares of common stock

From jeans to orange juice to laundry detergent: None would be possible without the activity of enzymes. Currently, enzymes used in industry are produced through an expensive, laborious fermentation process, requiring cold storage.

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the Cowen & Co. 39th Annual Health Care Conference on Wednesday, March 13th, 2019, at 10:40 a.m. ET in Boston, MA.